Advertisement

International Journal of Clinical Pharmacy

, Volume 38, Issue 4, pp 941–949 | Cite as

Improvements in the prescribing of antipsychotics in dementia and psychogeriatric units in New Zealand

  • June M. TordoffEmail author
  • Nagham J. Ailabouni
  • Dorothy P. Browne
  • Hesham S. Al-Sallami
  • Andrew R. Gray
Research Article

Abstract

Background Despite warnings of possible serious events, and reports of little benefit, antipsychotic agents are commonly prescribed in residential care for older people with dementia. A residential care provider (RCP) in New Zealand sought to examine and improve prescribing in some of their facilities. Objective To examine changes following a range of interventions implemented by a RCP to improve the prescribing of antipsychotics. Setting Thirteen dementia and psychogeriatric units in New Zealand managed by a RCP. Method An audit (n = 228 residents) was undertaken in thirteen dementia and psychogeriatric units in New Zealand in July–September 2011. A modified Best Practice Advocacy Centre (bpacnz) tool was used to examine antipsychotic prescribing, the administration of “when required” (PRN) antipsychotic doses and antipsychotic-related documentation (e.g. documenting of “target behaviour identified” and “need to monitor for adverse effects”). Prescribing for some central nervous system agents and fractures and fall rates were also examined. Some educational, managerial, environmental, recreational and resident-specific interventions were implemented post-audit. The audit (n = 233) was repeated in July–September 2013. Main outcome measures: (1) Number of residents prescribed and administered antipsychotics (2) Documentation of antipsychotic-related information in residents’ notes. Results The administration of antipsychotics and prescribing of regular doses (±PRN) decreased about a quarter from 2011 to 2013: 50.4–38.2, and 49.1–36.5 % (ORs 0.60, 0.57 respectively, both p < 0.001), and prescribing for any antipsychotic dose (including PRN only) decreased: 60.5–50.6 % (OR 0.67, p = 0.003). Documenting of “target behaviour identified” significantly increased from 54.3 to 71.2 %, (OR 1.99, p = 0.017) and documenting of the “need to monitor for adverse effects” increased non-significantly (30.4–46.6 %, p = 0.098); both falling short of the 90 % goal set by bpacnz. Benzodiazepine prescribing significantly decreased [39.0–25.8 %, (OR 0.59, p < 0.001)]. Conclusions Following a range of interventions, antipsychotic prescribing, administration and some related documentation improved in dementia and psychogeriatric units in New Zealand. Future studies should aim to identify the most effective of these interventions so they can be considered for implementing in similar settings.

Keywords

Antipsychotics Dementia Elderly New Zealand Nursing homes Older adults 

Notes

Acknowledgments

We thank the staff in each unit for facilitating the data collection, and staff at the Best Practice Advocacy Centre New Zealand for support and advice.

Funding

The Residential Care Provider provided funding to support the study, and information on the interventions implemented, but took no part in the design, execution, analysis and interpretation of data, or writing.

Conflicts of interest

The investigators have no conflicts of interest to declare.

References

  1. 1.
    World Health Organisation. Dementia. Fact sheet N°362. 2012. http://www.who.int/mediacentre/factsheets/fs362/en/. Accessed 15 Jan 2016.
  2. 2.
    Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157(5):708–14.CrossRefPubMedGoogle Scholar
  3. 3.
    Zimmerman S, Sloane PD, Reed D. Dementia prevalence and care in assisted living. Health Aff (Millwood). 2014;33(4):658–66.CrossRefGoogle Scholar
  4. 4.
    Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.CrossRefPubMedGoogle Scholar
  5. 5.
    Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627–32.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Food and Drug Administration (FDA). Public Health Advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. 2005. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm053171.htm. Accessed 15 Jan 2016.
  7. 7.
    Banerjee S. The use of antipsychotic medication in people with dementia: time for action. A report Commissioned by the Department of Health, UK. 2009. http://www.navarra.es/NR/rdonlyres/5CB1E6EB-F352-47B1-AE82-4CA073586C09/179929/PublicacionSubeBanerjee1.pdf Accessed 15 Jan 2016.
  8. 8.
    Royal Australian and New Zealand College of Psychiatrists (RANZCP). The use of antipsychotics in residential aged care. 2008. http://www.bpac.org.nz/a4d/ranzcpGuide.asp Accessed 3 Dec 2014.
  9. 9.
    Ballard C, Waite J, Birks J. Atypical anti-psychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD003476.PubMedGoogle Scholar
  10. 10.
    Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306(12):1359–69.CrossRefPubMedGoogle Scholar
  11. 11.
    Rolland Y, Andrieu S, Crochard A, Goni S, Hein C, Vellas B. Psychotropic drug consumption at admission and discharge of nursing home residents. J Am Med Dir Assoc. 2012;13(4):e7–12.CrossRefPubMedGoogle Scholar
  12. 12.
    Huber M, Kölzsch M, Rapp MA, et al. Antipsychotic drugs predominate in pharmacotherapy of nursing home residents with dementia. Pharmacopsychiatry. 2012;45(5):182–8.PubMedGoogle Scholar
  13. 13.
    Rattinger GB, Burcu M, Dutcher SK, et al. Pharmacotherapeutic management of dementia across settings of care. J Am Geriatr Soc. 2013;61(5):723–33.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Tucker M, Hosford I. Use of psychotropic medicines in residential care facilities for older people in Hawke’s Bay, New Zealand. N Z Med J. 2008;121(1274):18–25.PubMedGoogle Scholar
  15. 15.
    Jackson G, Gerard C, Minko N, Parsotam N. Variation in benzodiazepine and antipsychotic use in people aged 65 years and over in New Zealand. N Z Med J. 2014;127(1396):67–78.PubMedGoogle Scholar
  16. 16.
    Best Practice Advocacy Centre (BPAC). Antipsychotics in Dementia: Best Practice Guide. 2008. http://www.bpac.org.nz/a4d/resources/guide/guide.asp. Accessed 3 Dec 2014.
  17. 17.
    Central Region Technical Advisory Services Limited (TAS). Health of older people. Age Related Residential Care Services Agreement for the Provision of Age Related Residential Care. 2015. http://centraltas.co.nz/assets/Health-of-Older-People/ARRC-Agreement-effective-1-July-2015-v-20May2015.pdf. Accessed 15 Jan 2016.
  18. 18.
    Central Region Technical Advisory Services Limited (TAS). Health of older people. Age Related Residential Care Services Agreement for the Provision of Age Residential Hospital Specialised Services 2015. http://centraltas.co.nz/assets/Health-of-Older-People/ARHSS-Agreement-effective-1-July-2015-for-website-v-22May2015.pdf. Accessed 15 Jan 2016.
  19. 19.
    Eden Alternative. Mission, Vision, Values, Principles. 2014. http://www.edenalt.org/about-the-eden-alternative/mission-vision-values/. Accessed 15 Jan 2016.
  20. 20.
    Centers for Medicare and Medicaid Services. Press release: New data show antipsychotic drug use is down in nursing homes nationwide. 2013. http://www.cms.gov/Newsroom/MediaReleaseDatabase/Press-Releases/2013-Press-Releases-Items/2013-08-27.html. Accessed 15 Jan 2016.
  21. 21.
    Parsons C, Haydock J, Mathie E, et al. Sedative load of medications prescribed for older people with dementia in care homes. BMC Geriatr. 2011;11(56). doi: 10.1186/1471-2318-11-56.
  22. 22.
    Nishtala PS, McLachlan AJ, Bell JS, Chen TF. Determinants of antipsychotic medication use among older people living in aged care homes in Australia. Int J Geriatr Psychiatry. 2010;25(5):449–57.CrossRefPubMedGoogle Scholar
  23. 23.
    Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170(1):89–95.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Hughes CM, Donnelly A, Moyes SA, et al. “The way we do things around here”: an international comparison of treatment culture in nursing homes. J Am Med Dir Assoc. 2012;13(4):360–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Morrison A. Antipsychotic prescribing in nursing homes: an audit report. Qual Prim Care. 2009;17(5):359–62.PubMedGoogle Scholar
  26. 26.
    Nishtala PS, McLachlan AJ, Bell JS, Chen TF. Psychotropic prescribing in long-term care facilities: impact of medication reviews and educational interventions. Am J Geriatr Psychiatry. 2008;16(8):621–32.CrossRefPubMedGoogle Scholar
  27. 27.
    Westbury J, Jackson S, Gee P, Peterson G. An effective approach to decrease antipsychotic and benzodiazepine use in nursing homes: the RedUSe project. Int Psychogeriatr. 2010;22(1):26–36.CrossRefPubMedGoogle Scholar
  28. 28.
    Madhusoodanan S, Bogunovic OJ. Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf. 2004;3(5):485–9.CrossRefPubMedGoogle Scholar
  29. 29.
    American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616–31.CrossRefGoogle Scholar
  30. 30.
    Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer’s disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr. 2009;21(5):813–24.CrossRefPubMedGoogle Scholar
  31. 31.
    Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc. 2011;59(4):577–85.CrossRefPubMedGoogle Scholar
  32. 32.
    Tan L, Tan L, Wang HF, et al. Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis. Alzheimers Res Ther. 2015;7(1):20.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Coon JT, Abbott R, Rogers M, et al. Interventions to reduce inappropriate prescribing of antipsychotic medications in people with dementia resident in care homes: a systematic review. J Am Med Dir Assoc. 2014;15(10):706–18.CrossRefGoogle Scholar
  34. 34.
    Fossey J, Masson S, Stafford J, Lawrence V, Corbett A, Ballard C. The disconnect between evidence and practice: a systematic review of person-centred interventions and training manuals for care home staff working with people with dementia. Int J Geriatr Psychiatry. 2014;29(8):797–807.CrossRefPubMedGoogle Scholar
  35. 35.
    Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. J Am Geriatr Soc. 2011;59(6):1019–31.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Buckeridge D, Huang A, Hanley J, et al. Risk of injury associated with opioid use in older adults. J Am Geriatr Soc. 2010;58(9):664–70.CrossRefGoogle Scholar
  37. 37.
    Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169(21):1952-60. Erratum in: Arch Intern Med. 2010;170(5):477.Google Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  • June M. Tordoff
    • 1
    Email author
  • Nagham J. Ailabouni
    • 1
  • Dorothy P. Browne
    • 1
  • Hesham S. Al-Sallami
    • 1
  • Andrew R. Gray
    • 2
  1. 1.School of PharmacyUniversity of OtagoDunedinNew Zealand
  2. 2.Dunedin School of MedicineUniversity of OtagoDunedinNew Zealand

Personalised recommendations